Antonius P A Janssen
Overview
Explore the profile of Antonius P A Janssen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruijgrok G, Offen W, Pickles I, Raju D, Patsos T, de Boer C, et al.
J Am Chem Soc
. 2025 Feb;
147(10):8578-8586.
PMID: 39999423
During infection, the human opportunistic pathogen Pseudomonas aeruginosa forms protective biofilms, whose matrix consists of proteins, nucleic acids, and polysaccharides such as alginate, Psl, and Pel. Psl, a polymeric pentasaccharide...
2.
Schifferstein J, Bernatavicius A, Janssen A
J Chem Inf Model
. 2024 Dec;
64(24):9196-9204.
PMID: 39657274
Kinase inhibitors are an important class of anticancer drugs, with 80 inhibitors clinically approved and >100 in active clinical testing. Most bind competitively in the ATP-binding site, leading to challenges...
3.
Bernatavicius A, Sicho M, Janssen A, Hassen A, Preuss M, van Westen G
J Chem Inf Model
. 2024 Oct;
64(21):8113-8122.
PMID: 39475544
Recent advancements in deep learning and generative models have significantly expanded the applications of virtual screening for drug-like compounds. Here, we introduce a multitarget transformer model, , that leverages the...
4.
Bakker A, Kotsogianni I, Avalos M, Punt J, Liu B, Piermarini D, et al.
Nat Chem
. 2024 Jun;
16(9):1462-1472.
PMID: 38898213
Bacteria have evolved resistance to nearly all known antibacterials, emphasizing the need to identify antibiotics that operate via novel mechanisms. Here we report a class of allosteric inhibitors of DNA...
5.
Jia Y, Oyken M, Kim R, Tjokrodirijo R, de Ru A, Janssen A, et al.
J Med Chem
. 2024 May;
67(10):7935-7953.
PMID: 38713163
The integration of diverse chemical tools like small-molecule inhibitors, activity-based probes (ABPs), and proteolysis targeting chimeras (PROTACs) advances clinical drug discovery and facilitates the exploration of various biological facets of...
6.
De Paus L, An Y, Janssen A, van den Berg R, Heitman L, van der Stelt M
Chembiochem
. 2024 Feb;
25(7):e202300785.
PMID: 38372466
The cannabinoid receptor type 2 (CBR) is a G protein-coupled receptor with therapeutic potential for the treatment of inflammatory disorders. Fluorescent probes are desirable to study its receptor localization, expression...
7.
Jiang M, Huizenga M, Wirt J, Paloczi J, Amedi A, van den Berg R, et al.
Nat Commun
. 2023 Dec;
14(1):8039.
PMID: 38052772
Monoacylglycerol lipase (MAGL) regulates endocannabinoid 2-arachidonoylglycerol (2-AG) and eicosanoid signalling. MAGL inhibition provides therapeutic opportunities but clinical potential is limited by central nervous system (CNS)-mediated side effects. Here, we report...
8.
Li X, Chang H, Bouma J, De Paus L, Mukhopadhyay P, Paloczi J, et al.
Nat Commun
. 2023 Mar;
14(1):1447.
PMID: 36922494
Cannabinoid CB receptor (CBR) agonists are investigated as therapeutic agents in the clinic. However, their molecular mode-of-action is not fully understood. Here, we report the discovery of LEI-102, a CBR...
9.
Bakker A, Kotsogianni I, Mirenda L, Straub V, Avalos M, van den Berg R, et al.
J Am Chem Soc
. 2022 Dec;
145(2):1136-1143.
PMID: 36584241
Phenotypic screening is a powerful approach to identify novel antibiotics, but elucidation of the targets responsible for the antimicrobial activity is often challenging in the case of compounds with a...
10.
Gorostiola Gonzalez M, Janssen A, IJzerman A, Heitman L, van Westen G
Drug Discov Today
. 2022 Mar;
27(6):1661-1670.
PMID: 35301149
The integration of machine learning and structure-based methods has proven valuable in the past as a way to prioritize targets and compounds in early drug discovery. In oncological research, these...